Tela Bio, Inc. (TELA) — SEC Filings
Tela Bio, Inc. (TELA) — 41 SEC filings. Latest: 10-K (Mar 25, 2026). Includes 19 8-K, 6 10-Q, 4 SC 13G/A.
View Tela Bio, Inc. on SEC EDGAR
Overview
Tela Bio, Inc. (TELA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Mar 25, 2026: TELA Bio, Inc. reported significant operating losses for the fiscal year ended December 31, 2025, and anticipates continued losses, indicating challenges in achieving profitability. The company's revenue is highly dependent on its OviTex product line, which generated the vast majority of its sales.
Sentiment Summary
Across 41 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 37 neutral, 1 mixed. The dominant filing sentiment for Tela Bio, Inc. is neutral.
Filing Type Overview
Tela Bio, Inc. (TELA) has filed 3 10-K, 6 10-Q, 19 8-K, 2 DEF 14A, 4 SC 13G/A, 4 SC 13G, 3 SC 13D/A with the SEC between Feb 2024 to Mar 2026.
Filings by Year
Recent SEC Filings (41)
Risk Profile
Risk Assessment: Of TELA's 31 recent filings, 2 were flagged as high-risk, 13 as medium-risk, and 16 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | N/A |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | N/A |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Malvern, Pennsylvania
- Dr. David L. Alfery
- Mr. Jeffrey S. G. Smith
- Mr. Antony J. Loeser
- Mr. Robert L. Davis
- Kevin J. O'Malley
- Dr. David J. McVay
- Ms. Jennifer L. Chagnon
- Mr. Adam S. Cutler
- Taylor Ocasio
- Doug Evans
- Adrian Jones
Industry Context
The soft-tissue reconstruction market is characterized by a significant number of common surgical procedures like hernia repair, with an estimated U.S. total addressable market of $1.8 billion for TELA Bio's OviTex products. The industry is focused on developing solutions that balance clinical efficacy with economic value, often involving a mix of biologic and synthetic materials. Key trends include the drive for minimally invasive techniques (laparoscopic and robotic) and the generation of robust clinical data to support product adoption.
Top Tags
operations (6) · financials (5) · Medical Devices (4) · financial-reporting (4) · financial-condition (4) · 10-Q (4) · 8-K (3) · sec-filing (3) · ownership-change (3) · TELA Bio (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| U.S. Total Addressable Market | $1.8B | for OviTex products, indicating significant market potential |
| Hernia Recurrence Rate | 2.6% | at 24 months in BRAVO study for OviTex, demonstrating clinical efficacy |
| Surgical Site Occurrences | 38% | in BRAVO study, highlighting a potential complication rate |
| Patients Enrolled | 92 | in the BRAVO study, providing clinical data for OviTex |
| Shares Outstanding | 44,740,371 | as of March 16, 2026, relevant for valuation and ownership |
| Market Value of Non-Affiliate Common Stock | $76.8M | as of June 30, 2025, indicating market capitalization |
| Revenue for Q3 2025 | $20.689M | Increased from $18.957M in Q3 2024, showing 9.1% growth. |
| Revenue for nine months ended Sept 30, 2025 | $59.406M | Increased from $51.651M in the same period of 2024, showing 15.0% growth. |
| Net loss for Q3 2025 | $8.603M | Improved from a $10.372M net loss in Q3 2024. |
| Net loss for nine months ended Sept 30, 2025 | $29.790M | Increased from $28.633M in the same period of 2024. |
| Accumulated deficit as of Sept 30, 2025 | $388.5M | Increased from $358.730M at December 31, 2024, indicating continued unprofitability. |
| Cash and cash equivalents as of Sept 30, 2025 | $29.713M | Decreased significantly from $52.670M at December 31, 2024, highlighting cash burn. |
| Net cash used in operating activities for nine months ended Sept 30, 2025 | $23.349M | Reduced from $34.064M in the same period of 2024, but still a substantial outflow. |
| Common shares outstanding as of Nov 3, 2025 | 40,341,535 | Increased from 39,395,712 shares at December 31, 2024, indicating potential dilution. |
| Total stockholders' equity as of Sept 30, 2025 | $1.557M | Significantly decreased from $28.458M at December 31, 2024, reflecting substantial losses. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Tela Bio, Inc. (TELA)?
Tela Bio, Inc. has 41 recent SEC filings from Feb 2024 to Mar 2026, including 19 8-K, 6 10-Q, 4 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of TELA filings?
Across 41 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 37 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Tela Bio, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Tela Bio, Inc. (TELA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Tela Bio, Inc.?
Key financial highlights from Tela Bio, Inc.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for TELA?
The investment thesis for TELA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Tela Bio, Inc.?
Key executives identified across Tela Bio, Inc.'s filings include Malvern, Pennsylvania, Dr. David L. Alfery, Mr. Jeffrey S. G. Smith, Mr. Antony J. Loeser, Mr. Robert L. Davis and 7 others.
What are the main risk factors for Tela Bio, Inc. stock?
Of TELA's 31 assessed filings, 2 were flagged high-risk, 13 medium-risk, and 16 low-risk.
What are recent predictions and forward guidance from Tela Bio, Inc.?
Forward guidance and predictions for Tela Bio, Inc. are extracted from SEC filings as they are enriched.